

ASX / MEDIA RELEASE

13 DECEMBER 2016

APPOINTMENT OF PROFESSOR BRUCE ROBINSON AS NON-EXECUTIVE DIRECTOR

Cochlear Limited (ASX: COH) today announced the appointment of Prof Bruce Robinson to the Board of Cochlear Limited, effective from 13th December 2016.

Prof Robinson has over 20 years leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. He has extensive experience covering academia, government, public and private health providers, research institutes and philanthropic organisations.

His prior professional experience includes Dean, University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.

Since 2015, Prof Robinson has been the Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Schedule Review Taskforce. He is also currently an external director of MaynePharma, an ASX listed generic pharmaceutical manufacturer, Firefly, a medical device start-up and QBiotics, a drug development company.

Cochlear Chairman, Mr Rick Holliday-Smith welcomed Prof Robinson's appointment. "Bruce's deep experience in the medical field across research, academia, health administration and government as well as public and private health providers makes him an important addition to the Board."

Prof Robinson's appointment takes the number of Directors on the Cochlear Board to nine. He will be a non-executive Director and is considered by the Board to be independent.

For further information, please contact:

Analysts

Kristina Devon
Head of Investor Relations
Email: kdevon@cochlear.com
Ph: + 61 2 9611 6691

Media

Piers Shervington
Senior Manager Corporate Affairs
Email: pshervington@cochlear.com
Ph: +61 2 9425 5416